SSY Group Limited (HK:2005)
:2005
Want to see HK:2005 full AI Analyst Report?
Top Page
SSY Group
(2005)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$2.50
▼(-14.68% Downside)
Action:DowngradedDate:04/24/26
The score is driven mainly by mixed fundamentals: moderate balance-sheet risk and improved 2025 cash flow are positives, but the 2025 profitability and revenue decline is a meaningful headwind. Technicals are clearly bearish and pull the score down, while the dividend yield provides some valuation support.
Positive Factors
Balance-sheet strength
A moderate debt profile and steady asset growth provide financial flexibility and lower refinancing risk. This supports continued investment, M&A optionality, and the ability to withstand cyclical pressures, preserving strategic options over the next several quarters.
Negative Factors
2025 revenue and margin hit
A meaningful top-line decline and margin compression reduce earnings power and cash flow sustainably if persistent. This pressures reinvestment, dividend coverage and strategic spending, and may require execution on new products or cost restructuring to reverse.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
A moderate debt profile and steady asset growth provide financial flexibility and lower refinancing risk. This supports continued investment, M&A optionality, and the ability to withstand cyclical pressures, preserving strategic options over the next several quarters.
Read all positive factors
SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.96B
Dividend Yield4.93%
Average Volume (3M)5.65M
Price to Earnings (P/E)17.6
Beta (1Y)0.65
Revenue Growth-27.85%
EPS Growth-55.43%
CountryHK
Employees6,146
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.06
Shares Outstanding2,951,113,300
10 Day Avg. Volume4,536,404
30 Day Avg. Volume5,652,093
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.14
Price to Sales (P/S)1.99
P/FCF Ratio27.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.76Price Target Upside28.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$4.88B
SSY Group Business Overview & Revenue Model
Company Description
SSY Group (2005) is a diversified company specializing in the manufacturing and distribution of pharmaceuticals and healthcare products. With a strong emphasis on quality and innovation, SSY Group operates in various sectors including generic phar...
SSY Group Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
70
Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.17B | 5.77B | 6.46B | 6.43B | 5.36B |
| Gross Profit | 1.62B | 2.91B | 3.62B | 3.44B | 3.04B |
| EBITDA | 859.74M | 1.74B | 2.11B | 1.86B | 1.40B |
| Net Income | 470.64M | 1.06B | 1.32B | 1.12B | 785.53M |
Balance Sheet | |||||
| Total Assets | 12.81B | 12.60B | 11.97B | 10.97B | 10.71B |
| Cash, Cash Equivalents and Short-Term Investments | 1.82B | 1.29B | 1.62B | 1.71B | 1.70B |
| Total Debt | 4.01B | 3.64B | 3.37B | 3.21B | 3.11B |
| Total Liabilities | 5.19B | 5.07B | 4.70B | 4.42B | 4.22B |
| Stockholders Equity | 7.30B | 7.22B | 6.93B | 6.21B | 6.22B |
Cash Flow | |||||
| Free Cash Flow | 299.78M | -49.39M | 221.88M | 368.70M | 359.58M |
| Operating Cash Flow | 635.03M | 491.03M | 925.75M | 786.82M | 747.91M |
| Investing Cash Flow | 77.02M | -521.76M | -640.19M | -402.72M | -681.23M |
| Financing Cash Flow | -293.69M | -295.42M | -304.57M | -190.51M | 136.13M |
SSY Group Technical Analysis
Negative
2.93
Price Trends
2.64
Negative
2.81
Negative
2.90
Negative
Market Momentum
-0.03
Negative
45.50
Neutral
51.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2005, the sentiment is Negative. The current price of 2.93 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.64, and above the 200-day MA of 2.90, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 51.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2005.
SSY Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$7.44B | 6.31 | 11.90% | 5.80% | -17.03% | 12.82% | |
72 Outperform | HK$1.71B | 7.90 | 6.34% | 5.16% | 16.09% | -62.16% | |
67 Neutral | HK$779.10M | 3.58 | 12.80% | 7.52% | -9.66% | 16.17% | |
58 Neutral | HK$6.96B | 17.64 | 9.09% | 4.93% | -27.85% | -55.43% | |
54 Neutral | HK$8.56B | -28.37 | -1.64% | 3.66% | -10.68% | -737.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$356.60M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% |
* Healthcare Sector Average
HK:2005
SSY Group
2.36
-0.45
-15.95%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.70
-0.24
-12.46%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.32
-0.03
-8.57%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.14
0.07
6.54%
HK:0239
Pak Fah Yeow International Limited
2.50
0.39
18.48%
HK:2877
China Shineway Pharmaceutical Group Limited
9.85
2.71
37.96%
SSY Group Corporate Events
SSY Group Sets 2026 AGM to Approve Results, Dividend and Share Issuance Mandate
Apr 21, 2026
SSY Group has called its annual general meeting for 15 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025, re-elect three directors, and confirm the rem...
SSY Group Wins China Approval for Furosemide Bulk Drug
Apr 21, 2026
SSY Group Limited has secured approval from China’s National Medical Products Administration for its Furosemide as a bulk drug, enabling its use in the manufacture of preparations already on the market. This follows earlier regulatory approv...
SSY Group Wins NMPA Approvals for New Electrolyte and Antiemetic Injections
Apr 10, 2026
SSY Group Limited has received approvals from China’s National Medical Products Administration for the production and registration of its Multiple Electrolytes, Sodium Acetate and Glucose Injection in 250ml and 500ml formats, as well as its ...
SSY Group Wins China Approval for Upadacitinib Bulk Drug
Mar 31, 2026
SSY Group Limited is a Hong Kong-based pharmaceutical group active in China, specializing in the development and manufacture of bulk drugs and related preparations. The company targets major chronic and inflammatory conditions, aiming to deepen it...
SSY Group Wins China Approval for New Irrigation and Bumetanide Injectables
Mar 27, 2026
SSY Group has received Chinese regulatory approvals for production and registration of its Sodium Lactate Ringer’s Irrigation Solution (3000ml) and Bumetanide Injection (2ml:1mg), both classified as type 3 chemical drugs that have passed con...
SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025
Mar 27, 2026
SSY Group reported a sharp deterioration in 2025 results as shrinking demand, tighter policies and intensifying competition hit its pharmaceutical business, with revenue falling 27.8% to about HK$4.17 billion and net profit dropping 55.6% to HK$47...
SSY Group Declares Final Cash Dividend of HKD 0.03 per Share for 2025
Mar 27, 2026
SSY Group Limited has declared a final ordinary cash dividend of HKD 0.03 per share for the financial year ended 31 December 2025, with payment scheduled for 4 June 2026 to shareholders on record as of 21 May 2026. The dividend, which remains subj...
SSY Group Wins China Approval for Calcium Chloride Bulk Drug
Mar 19, 2026
SSY Group has secured approval from China’s National Medical Products Administration for its Calcium Chloride to be registered as a bulk drug for existing market preparations. This regulatory green light broadens the group’s injectable...
SSY Group Sets March 2026 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 17, 2026
SSY Group Limited has scheduled a board meeting for 27 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. At the same meeting, the board will also consider whether...
SSY Group Wins China Approval for Bumetanide Bulk Drug
Mar 16, 2026
SSY Group Limited has secured approval from China’s National Medical Products Administration for its Bumetanide bulk drug, enabling its use in the production of market-ready preparations. The product is a loop diuretic indicated for a wide r...
SSY Group Wins First PRC Approval for New Fat-Soluble Vitamin Injection
Mar 13, 2026
SSY Group has received approval from China’s National Medical Products Administration to produce and register its Fat-soluble Vitamin Injection (Ⅱ) 10ml, classified as a type 3 chemical drug that has passed consistency evaluation. The ...
SSY Group Wins China Approval for Homegrown High-Performance Infusion Tubing
Mar 13, 2026
SSY Group Limited has received approval from China’s National Medical Products Administration for its 3000ml sodium chloride physiological solution to use three-layer co-extruded infusion tubing produced by its subsidiary Jiangsu Best New Me...
SSY Group Wins China Approval for New Oncology Injection
Mar 6, 2026
SSY Group has received approval from China’s National Medical Products Administration to produce and register its Calcium Levofolinate for Injection 25mg, classified as a type 3 chemical drug that has passed consistency evaluation. The injec...
SSY Group Wins First-in-China Approval for Doxapram Injection
Mar 3, 2026
SSY Group Limited has received regulatory approval from China’s National Medical Products Administration for its Doxapram Hydrochloride Injection (5ml:100mg), classified as a type 3 chemical drug that has passed consistency evaluation. The p...
SSY Group Wins Hebei Approval for Gynecological Gel and Heart Failure Test Kit
Feb 27, 2026
SSY Group Limited has expanded its medical device portfolio in China, securing registration certificates from the Hebei Provincial Drug Administration for a Medical Recombinant Collagen Gynecological Gel and a B-type Natriuretic Peptide (BNP) Test...
SSY Group Wins NMPA Approval for Metoclopramide Bulk Drugs
Feb 27, 2026
SSY Group Limited has received approval from China’s National Medical Products Administration for the registration of its Metoclopramide and Metoclopramide Hydrochloride as bulk drugs used in market preparations. These dopamine D2 antagonist...
SSY Group Issues Profit Warning as Pricing and Demand Pressures Hit 2025 Earnings
Feb 16, 2026
SSY Group has warned that profit attributable to equity shareholders for 2025 is expected to fall by 45% to 60% from HK$1.06 billion in 2024, driven by weaker turnover amid a normalized post-influenza demand environment in China. The company cited...
SSY Group Wins China Approval for Propranolol Bulk Drug
Feb 13, 2026
SSY Group Limited has obtained approval from China’s National Medical Products Administration for its Propranolol Hydrochloride to be registered as a bulk drug for use in market preparations. The beta-blocker product targets key cardiovascul...
SSY Group Wins 45 Drug Selections in China’s National Centralised Procurement Renewal
Feb 10, 2026
SSY Group Limited has secured selection for 45 of its pharmaceutical products in the latest renewal round of China’s National Centralised Medicines Procurement, covering the first to eighth procurement batches. The winning products span majo...
SSY Group Wins NMPA Approvals for Two New Bulk Drug Products
Feb 9, 2026
SSY Group Limited has secured approvals from China’s National Medical Products Administration for Phloroglucinol Trimethyl Ether and Dobutamine Hydrochloride as bulk drugs for market-ready preparations, deepening its presence in injectables....
SSY Group Wins NMPA Approval for New Cardiac Injection
Jan 30, 2026
SSY Group Limited has secured approval from China’s National Medical Products Administration for the production and registration of its Propafenone Hydrochloride Injection (20ml:70mg), classified as a type 3 chemical drug and deemed to have ...
SSY Group Wins China Approval for New Specification of Nutritional Injection
Jan 26, 2026
SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register a new 2ml specification of its Composite Potassium Hydrogen Phosphate Injection, classified as a type 3 chemical drug and d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.